CN103249408A - 利用多不饱和长链酮类的类风湿性关节炎治疗 - Google Patents

利用多不饱和长链酮类的类风湿性关节炎治疗 Download PDF

Info

Publication number
CN103249408A
CN103249408A CN2011800520405A CN201180052040A CN103249408A CN 103249408 A CN103249408 A CN 103249408A CN 2011800520405 A CN2011800520405 A CN 2011800520405A CN 201180052040 A CN201180052040 A CN 201180052040A CN 103249408 A CN103249408 A CN 103249408A
Authority
CN
China
Prior art keywords
group
chemical compound
linking group
ring
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800520405A
Other languages
English (en)
Chinese (zh)
Inventor
阿斯特丽德·尤鲁姆斯特罗福伊尔黑尔姆
贝丽特·约翰森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coegin Pharma AS
Original Assignee
Avexxin AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avexxin AS filed Critical Avexxin AS
Priority to CN201811592300.8A priority Critical patent/CN109893518A/zh
Publication of CN103249408A publication Critical patent/CN103249408A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/22—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN2011800520405A 2010-09-02 2011-09-01 利用多不饱和长链酮类的类风湿性关节炎治疗 Pending CN103249408A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811592300.8A CN109893518A (zh) 2010-09-02 2011-09-01 多不饱和长链酮类或其盐在制备用于治疗类风湿性关节炎的药物中的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1014633.0A GB201014633D0 (en) 2010-09-02 2010-09-02 Rheumatoid arthritis treatment
GB1014633.0 2010-09-02
PCT/EP2011/065123 WO2012028688A1 (en) 2010-09-02 2011-09-01 Rheumatoid arthritis treatment using polyunsaturated long chain ketones

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811592300.8A Division CN109893518A (zh) 2010-09-02 2011-09-01 多不饱和长链酮类或其盐在制备用于治疗类风湿性关节炎的药物中的用途

Publications (1)

Publication Number Publication Date
CN103249408A true CN103249408A (zh) 2013-08-14

Family

ID=43013608

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011800520405A Pending CN103249408A (zh) 2010-09-02 2011-09-01 利用多不饱和长链酮类的类风湿性关节炎治疗
CN201811592300.8A Pending CN109893518A (zh) 2010-09-02 2011-09-01 多不饱和长链酮类或其盐在制备用于治疗类风湿性关节炎的药物中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201811592300.8A Pending CN109893518A (zh) 2010-09-02 2011-09-01 多不饱和长链酮类或其盐在制备用于治疗类风湿性关节炎的药物中的用途

Country Status (10)

Country Link
US (1) US9682930B2 (https=)
EP (1) EP2611432A1 (https=)
JP (2) JP6082347B2 (https=)
KR (1) KR20130112880A (https=)
CN (2) CN103249408A (https=)
AU (1) AU2011298340B2 (https=)
CA (1) CA2810102A1 (https=)
GB (1) GB201014633D0 (https=)
IL (1) IL224963A (https=)
WO (1) WO2012028688A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106458877A (zh) * 2014-05-27 2017-02-22 埃维克辛公司 皮肤癌的治疗
CN109789111A (zh) * 2016-09-21 2019-05-21 埃维克辛公司 药物组合物
CN110996931A (zh) * 2017-06-16 2020-04-10 埃维克辛公司 用于治疗纤维化疾病的组合物和方法
US10953004B2 (en) 2016-03-14 2021-03-23 Avexxin As Combination therapy for proliferative diseases

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
CA2794171C (en) 2010-03-24 2018-07-03 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
GB201205394D0 (en) 2012-03-27 2012-05-09 Adlens Ltd Improvements in or relating to deformable non-round membrane assemblies
GB201221329D0 (en) 2012-11-27 2013-01-09 Avexxin As Dermatitis treatment
GB201313238D0 (en) 2013-07-24 2013-09-04 Avexxin As Process for the preparation of a polyunsaturated ketone compound
GB201501144D0 (en) 2015-01-23 2015-03-11 Avexxin As Process for the preparation of a polyunsaturated ketone compound
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
CA3115122A1 (en) 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
EP3930702A1 (en) 2019-03-01 2022-01-05 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
GB201910644D0 (en) 2019-07-25 2019-09-11 Coegin Pharma As Cancer Treatment
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US20210311022A1 (en) * 2020-03-27 2021-10-07 Organogenesis, Inc. Methods, kits and compositions for characterizing an anti-inflammatory response of a product
WO2022076824A1 (en) 2020-10-08 2022-04-14 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
EP4312597A4 (en) * 2021-03-23 2025-01-22 Organogenesis, Inc. METHODS, KITS AND COMPOSITIONS FOR CHARACTERIZING AN ANTI-INFLAMMATORY RESPONSE OF A PRODUCT
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
JP2026513019A (ja) 2023-02-03 2026-04-22 トリス・フアルマ・インコーポレーテツド １晩１回の低ナトリウムオキシベート組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060535A1 (en) * 2001-01-31 2002-08-08 Leff Alan R Method of treating inflammatory conditions by inhibiting cytosolic phospholipase a¿2?

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670465A (en) * 1986-05-21 1987-06-02 Syntex (U.S.A.) Inc. Arachidonic acid analogs
JPH0987176A (ja) 1995-09-26 1997-03-31 Shiseido Co Ltd 糸球体腎炎抑制剤
JPH09268153A (ja) 1996-04-02 1997-10-14 Sagami Chem Res Center トリフルオロメチルケトン誘導体及びホスホリパーゼａ２阻害剤
WO1997038688A1 (en) * 1996-04-12 1997-10-23 Peptide Technology Pty. Limited Methods of treating immunopathologies using polyunsaturated fattyacids
EP1140791A4 (en) 1997-09-23 2001-10-10 Bristol Myers Squibb Co SELECTIVE CPLA 2 INHIBITORS
US6107334A (en) 1998-02-23 2000-08-22 Wake Forest University Dietary control of arachidonic acid metabolism
US7605149B1 (en) 1998-07-13 2009-10-20 University Of South Florida Modulation of the phospholipase A2 pathway as a therapeutic
US6031014A (en) 1998-12-08 2000-02-29 Crivello; James V. Initiator compositions and methods for their synthesis and use
CA2379208A1 (en) 1999-07-19 2001-01-25 Eli Lilly & Company Spla2 inhibitors
EP1243524A3 (en) 2001-03-16 2004-04-07 Pfizer Products Inc. Pharmaceutical kit for oxygen-sensitive drugs
US7101875B2 (en) * 2001-12-03 2006-09-05 Wyeth Methods for treating arthritic disorders
GB0202002D0 (en) 2002-01-29 2002-03-13 Leiv Eiriksson Nyotek A S Use
MY131170A (en) 2002-03-28 2007-07-31 Nissan Chemical Ind Ltd Therapeutic agent for glomerular disease
US20040111957A1 (en) 2002-12-13 2004-06-17 Filippini Brian B. Water blended fuel composition
WO2006106438A2 (en) * 2005-01-11 2006-10-12 Evolva Sa Modulators of ppar activity
US20060246115A1 (en) * 2005-03-04 2006-11-02 Ricardo Rueda Nutritional products for ameliorating symptoms of rheumatoid arthritis
NZ552238A (en) 2006-12-20 2009-07-31 Seperex Nutritionals Ltd An extract
US20100144827A1 (en) 2006-12-20 2010-06-10 Medwell Laboratories Ltd. C/O Ngt Technological Incubator Novel conjugates of polyunsaturated fatty acids with amines and therapeutic uses thereof
CA2699483A1 (en) * 2007-09-14 2009-03-26 Resolvyx Pharmaceuticals, Inc. Compositions and methods for modulating immune function
WO2009061208A1 (en) 2007-11-09 2009-05-14 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
US8211947B2 (en) * 2008-01-28 2012-07-03 Guillermo Selman-Housein Sosa Composition and method for treating and preventing musculoskeletal and connective tissue disorders
EP2147910A1 (en) 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
BRPI1015120B8 (pt) * 2009-05-08 2022-02-15 Basf As Composto lipídico alfa-substituídos, derivados de ácidos graxos beta-oxo poli-insaturados, composição farmacêutica e lipídica e métodos para produzir composto lipídico e ácido 2-((5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaeniloxi)butanóico
GB0909643D0 (en) * 2009-06-04 2009-07-22 Avexxin As Glomerulonephritis treatment
US20130137767A1 (en) * 2010-02-02 2013-05-30 Dsm Ip Assets B.V. Methods and Compositions for Treating Arthritis with Docosahexaenoic Acid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060535A1 (en) * 2001-01-31 2002-08-08 Leff Alan R Method of treating inflammatory conditions by inhibiting cytosolic phospholipase a¿2?

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANNE KRISTIN HOLMEIDE等: "Syntheses of some polyunsaturated trifluoromethyl ketones as potential phospholipase A2 inhibitors", 《JOURNAL OF CHEMICAL SOCIETY,PERKIN TRANSACTIONS 1》, 30 June 2000 (2000-06-30) *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106458877A (zh) * 2014-05-27 2017-02-22 埃维克辛公司 皮肤癌的治疗
US10085953B2 (en) 2014-05-27 2018-10-02 Avexxin As Skin cancer treatment
US10953004B2 (en) 2016-03-14 2021-03-23 Avexxin As Combination therapy for proliferative diseases
CN109789111A (zh) * 2016-09-21 2019-05-21 埃维克辛公司 药物组合物
CN109789111B (zh) * 2016-09-21 2021-11-16 埃维克辛公司 药物组合物
US11351127B2 (en) 2016-09-21 2022-06-07 Avexxin As Pharmaceutical composition
CN110996931A (zh) * 2017-06-16 2020-04-10 埃维克辛公司 用于治疗纤维化疾病的组合物和方法
CN110996931B (zh) * 2017-06-16 2023-12-15 埃维克辛公司 用于治疗纤维化疾病的组合物和方法

Also Published As

Publication number Publication date
US20130245127A1 (en) 2013-09-19
EP2611432A1 (en) 2013-07-10
CN109893518A (zh) 2019-06-18
WO2012028688A1 (en) 2012-03-08
KR20130112880A (ko) 2013-10-14
JP2013540713A (ja) 2013-11-07
CA2810102A1 (en) 2012-03-08
IL224963A (en) 2017-09-28
JP2017075148A (ja) 2017-04-20
AU2011298340A1 (en) 2013-03-28
JP6082347B2 (ja) 2017-02-15
GB201014633D0 (en) 2010-10-13
US9682930B2 (en) 2017-06-20
AU2011298340B2 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
CN103249408A (zh) 利用多不饱和长链酮类的类风湿性关节炎治疗
CN103751194B (zh) 用于治疗病症的方法和组合物
KR101853971B1 (ko) 매우 높은 피부 및 막 침투율을 가지는 비스테로이드성 소염제(ｎｓａｉａ) 약물전구체 및 이들의 새로운 의약적 용도
JP6689078B2 (ja) 超高純度なテトラヒドロカンナビノール−１１−酸
KR20090034395A (ko) 운데카프레닐 피로포스페이트 합성효소의 억제제
US20150087705A1 (en) Protective Effects of Curcumin Against Hemorrhagic Stroke Injury
NO175148B (no) Fremgangsmåte for fremstilling av et indomethacinsalt av et toverdig metall valgt fra kobber, sink, kobolt og nikkel
CN115304593B (zh) 苯并异噻唑化合物及其药物组合物和应用
IL186072A (en) Use of a benzoyl derivative of 3-aminocarbazole for the production of a drug for the treatment of a disorder associated with the production of prostaglandin e2 (pge2)
JPH06509110A (ja) 胃及び十二指腸障害を治療する方法及び組成物並びに新規なｐｇｅ↓２誘導体
TW200827343A (en) Novel phenylacetic acid derivative
CN115605455B (zh) 酮洛芬、赖氨酸和加巴喷丁的共晶、药物组合物及其医药用途
CN111303161B (zh) 嘧啶并氮杂环类化合物及其用途
CN108640916A (zh) 一类具有抗癌活性的硫代吲嗪类化合物及其衍生物
CN110251498A (zh) 一类调节法尼醇受体活性的化合物及其用途
WO2022238741A1 (en) Coumarin compounds and a process for preparation thereof
WO2024074116A1 (zh) 咪唑烷基香草酸醚衍生物治疗伴随有纤维化的疾病的用途
JPH10175969A (ja) ホルボールエステル誘導体
CN101684099A (zh) 取代芳香环、芳香杂环的丙酸衍生物、其制备方法和用途
JPS5913723A (ja) 細胞保護作用を有する医薬及び１３−チア−プロスタグランジン誘導体の使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130814